Disco Pharmaceuticals
Pre-clinicalOur mission is to improve patient care by unleashing the full potential of targeted cancer therapies using our transformative cell surfaceome discovery technology.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $43M
About
Our mission is to improve patient care by unleashing the full potential of targeted cancer therapies using our transformative cell surfaceome discovery technology.
AntibodiesBiologics
Funding History
2Total raised:$43M
Series A$35MSep 15, 2023
Seed$8MMar 15, 2022